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Background: Inflammation plays an important albeit dual role in carcinogenesis. Survival
studies have highlighted the prognostic significance of peritumorous inflammation.
Currently, the theoretical background allows inflammation, epithelial mesenchymal transition
(EMT) and the closely associated stem cell differentiation in colorectal carcinoma (CRC) to
be linked. However, there is scarce direct morphological evidence.
Purpose and methods: The aim of our study was to investigate the role of inflammation in
cancer growth and invasion by analyzing the association between inflammation and known
morphological prognostic features of colorectal cancer, EMT, stemness and mismatch repair
(MMR) protein expression. The study was designed as a retrospective morphological and
immunohistochemical assessment of 553 consecutive cases of surgically treated primary CRC.
Results: There were statistically significant associations between high-grade inflammation
and lower pT (p = 0.002), absence of lymph node metastases (p < 0.001) and less frequent
lymphatic (p = 0.003), venous (p = 0.017), arterial (p = 0.012), perineural (p = 0.001) and
intraneural (p = 0.01) invasion. In contrast, Crohn’s like reaction (CLR) by density of
lymphoid follicles in the invasive front lacked significant differences in regard to pT, pN,
tumor invasion into surrounding structures (blood or lymphatic vessels, nerves), grade or
necrosis (all p > 0.05). The expression of E-cadherin, CD44 and MMR proteins yielded no
statistically significant associations with peritumorous inflammation by Klintrup-Mäkinen
score or the density of lymphoid follicles. Nevertheless, E-cadherin levels were significantly
associated with the density of eosinophils (p = 0.007).
Conclusion: High-grade peritumorous inflammation is associated with beneficial morpholo-
gic CRC features, including less frequent manifestations of invasion, and is not secondary to
tissue damage and necrosis. CLR is not associated with cancer spread by pTN; this finding
indirectly suggests an independent role of CLR in carcinogenesis. Further, inflammation by
Klintrup-Mäkinen grade and CLR is not dependent on epithelial-mesenchymal transition and
stem cell differentiation. Our study highlights the complex associations between inflammation,
tumor morphology, EMT, stemness and MMR protein expression in human CRC tissues.
Keywords: colorectal carcinoma, inflammation,Klintrup-Mäkinen score, immunohistochemistry,
CD44, mismatch repair proteins
Introduction
Every year, colorectal cancer is responsible for many deaths worldwide. Thus, it
still ranks globally among the three deadliest cancers.1 Nowadays, there are exten-
sive possibilities for prevention, screening or timely diagnostics of colorectal
carcinoma. Fecal guaiac occult blood testing or immunochemical tests, stool
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DNA tests, computed tomography colonography, double-
contrast barium enemas, sigmoidoscopy and colonoscopy
have been implemented for screening.2,3 All positive
screening results obtained by any noncolonoscopy method
should be followed by timely colonoscopy.4 The guide-
lines for screening are available, as recently systematically
reviewed by Benard et al5. Screening has been shown to
reduce mortality.6 For instance, screening by fecal occult
blood test reduces the relative risk of colorectal cancer
mortality by 25%. Colonoscopy is associated with a 67%
reduction in the incidence of colorectal cancer within the
next eight years, due to its greater potential to disclose and
remove adenomas.2 Based on case control and prospective
cohort studies, it is also suggested that it reduces mortality
by 65–88%.4 In the USA, the incidence of colorectal
carcinoma in people aged 50 or older declined by 32%
between 2000 and 2013 and CRC- related mortality by
34% between 2000 and 2014. These changes have been
attributed to the screening and removal of adenomas.4
A wide array of treatment approaches is available,
including local treatment (endoscopic or transanal excision
followed by a wider resection and lymph node dissection
if certain unfavorable histologic features are identified),
surgery with lymph node dissection via a laparoscopic or
conventional approach, irradiation, and adjuvant or sys-
temic chemotherapy (to prevent postoperative recurrence
or to treat an unresectable progressive tumor, respectively)
including molecular targeted drugs. To establish a standard
medical treatment of consistent quality, guidelines are
issued and revised by the National Comprehensive
Cancer Network (NCCN) in the USA, the European
Society for Medical Oncology (ESMO) and the Japanese
Society for Cancer of the Colon and Rectum.7
Extensive local spread and/or large size of the tumor,
the presence of metastases in lymph nodes, mucinous
differentiation, invasion into lymphatic vessels, perineural
growth and peritoneal involvement all indicate an unfavor-
able prognosis of colorectal carcinoma.8–10 Recently, the
prognostic importance of the extent of cancer necrosis has
been discussed.11 These factors could show bidirectional
associations with chronic inflammation, which is an
important component of tumor pathogenesis, beginning
from the initiation and accompanying the progression
and spread.
Inflammation is increasingly recognized as an important
component of carcinogenesis. In colorectal cancer, it is known
to influence the risk of developing cancer. Certain inflamma-
tory diseases, such as Crohn’s disease and ulcerative colitis,
increase the risk of colorectal carcinoma. In contrast, nonster-
oidal anti-inflammatory drugs, such as aspirin and selective
inhibitors of cyclooxygenase-2, in epidemiological, observa-
tional and clinical studies have been shown to be effective tools
for decreasing the risk of colorectal cancer, the recurrence of
adenomas and the development of new tumors. Regression of
existing adenomas has been reported as well.12 Hence, inflam-
mation is known to be among the risk factors for malignant
change not only in the large bowel but also in the stomach and
uterine cervix.13 In an already established tumor, inflammatory
reaction can either promote or suppress tumor progression.
Inflammatory cells are able to produce growth factors stimu-
lating the proliferation of neoplastic cells, to enhance angio-
genesis or to degrade the connective tissue matrix that in turn
facilitates invasion. Consequently, inflammation might create
a microenvironment that is beneficial for tumor development.
On the other hand, inflammation can induce cancer cell
death.14,15 One of the main factors involved in tumor progres-
sion is the pro-inflammatory cytokine TNFα, produced by
macrophages. TNFα also has a crucial role in epithelial
mesenchymal transition (EMT) as it induces overexpression
of the transcription factor Snail, leading to downregulation of
E-cadherin and upregulation of N-cadherin,16,17 which are
among the key molecules involved in EMT. In colorectal
cancer, stem cell differentiation by expression of CD4418 is
strongly associated with EMT19 and represents an attractive
treatment target.20 However, the relation between CD44 levels
and inflammation has not been extensively studied.
The response to treatment can depend on the degree of
tumor heterogeneity. This is the case not only in colorectal
cancer21 but also in other carcinomas22 in relation to
cancer stem cells.23 With regard to colorectal cancer, the
heterogeneity is more frequent in tumors exhibiting micro-
satellite instability (MSI) than in microsatellite-stable
(MSS) carcinomas.24 Changes within the mismatch repair
(MMR) protein expression via immunohistochemistry
(IHC) could be the hallmark for further DNA sequencing
and personalized treatment choice.
As regards colorectal carcinoma, patients featuring intense,
high-grade peritumorous inflammation have better survival
rates than those who have low-grade inflammation.25,26
Some studies have revealed links between decreased CD44
expression and resistance to chemotherapy27 or recurrence of
colorectal cancer.28 A combined low expression of E-cadherin
and CD44 is associated with decreased overall survival in
patients with metastatic colorectal cancer.29 Given these prog-
nostic trends, associations between the listed factors might be
hypothesized. However, few studies have tried to assess
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directly the mutual relationships between inflammation, EMT,
stem cell differentiation and the expression of MMR proteins
in the same cohort of colorectal cancer cases.
The aim of our study was to investigate the association
between peritumorous inflammation and known adverse
morphological features of colorectal carcinoma, including
local spread (pT), the involvement of regional lymph
nodes (pN) and manifestations of invasive growth as
well as the molecular landscape of EMT, cancer stem
cell differentiation and the expression of MMR proteins.
Materials and Methods
Ethics Statement
The study was designed as a retrospective morphological and
immunohistochemical investigation of a representative
group of consecutive, surgically treated colorectal carcinoma
cases. It was carried out in accordance with the Declaration
of Helsinki and was approved by the Committee of Ethics of
Riga Stradins University, Riga, Latvia. Considering the retro-
spective study design, patient consent to review their medical
records and tissue sections was not required by the said
institutional research board. All the patient data were treated
confidentially and anonymously.
Study Group
Diagnostic histopathology reports and slides of colorectal
cancer were retrieved by archive search for consecutive
patients who underwent radical surgical treatment of primary
invasive colorectal carcinoma in a single university hospital
within a four-year period. Cases were excluded from the study
on the basis of the following characteristics of the patient or
tumor: 1) previous history of colorectal cancer; 2) nonsurgical
treatment; 3) palliative operation; 4) tissue material limited to
a biopsy; 5) tumor fragmentation during surgery precluding
reliable pathological staging; 6) pTis carcinoma; 7) secondary
tumor involving the large bowel; and 8) tumor of nonepithelial
histogenesis. Demographic data (age and gender) were
retrieved from the medical documentation.
Tissue Samples
During the initial diagnostic evaluation, the surgical
pathology materials were subjected to uniform protocol-
based assessment including standardized grossing and
sampling. The protocol was based on the recommenda-
tions issued by the College of American Pathologists.30
The tumor location by the side of the large bowel (right vs
left) was retrieved from the medical documentation. The
tissues were routinely fixed in 10% neutral buffered formalin
(Sigma-Aldrich, Saint Louis, USA), processed via vacuum
infiltration, embedded in paraffin, cut to a thickness of 4
micrometers and stained with hematoxylin and eosin (HE).
Within the frames of the current study, the retrieved diagnostic
pathology slideswere re-evaluated by two observers in order to
reach consensus on all the investigated parameters in each
case. The cancer morphology, including grading, and pTN
parameters were assessed according to the World Health
Organization and the Union for International Cancer Control
(UICC)TNMclassification.31,32 To evaluate the invasive capa-
city of the tumour, the presence of perineural and intraneural
cancer growth and invasion into lymphatic vessels, veins and
arteries were assessed as categorical binary variables.33 Cancer
necrosis was analyzed as a binary variable (present versus
absent) and by the extent,34 classifying the necrosis as focal
(< 10%of thewhole tumour), moderate (10–30%) or extensive
(> 30%) in line with Richards et al, 2012.
Assessment of Inflammation
Peritumorous inflammation was assessed according to the
Klintrup-Mäkinen inflammation score by identifying four
groups, ie absent versus mild versus moderate versus severe
inflammation, which were further redistributed into two
classes, namely low-grade (absent or mild inflammation)
versus high-grade (moderate or severe) inflammation.26
Inflammatory cell subpopulations were evaluated by an ana-
logous four-tiered scale.35 The degree of Crohn’s like lym-
phoid reaction (CLR) was assessed as CLR density
according to Väyrynen criteria, by counting CLR follicles
in the invasive front of a tumor.36 Further, the CLR results
were redistributed into two groups, namely low versus high
CLR density, using a previously verified threshold value,36
i.e. < 0.38 versus ≥ 0.38 per mm.
Immunohistochemistry
To evaluate epithelial-mesenchymal transition, stem cell dif-
ferentiation and the expression of MMR proteins, immunohis-
tochemical visualization of E-cadherin, CD44 and the MMR
proteins MSH2, MSH6, MLH1 and PMS2 was performed on
whole sections from representative blocks of the tumour. For
IHC, 3-micrometer thick sections were cut on electrostatic
glass slides (Histobond, Marienfeld, Germany). After depar-
affinization and rehydration, antigen retrieval was performed
in a microwave oven (3 × 5 min) using a basic TEG (pH 9.0)
buffer, followed by blocking of endogenous peroxidase
(Sigma-Aldrich). The sections were incubated with primary
antibodies (see Table 1 for antibody characteristics and
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dilution) at room temperature. Bound antibodies were detected
by the enzyme-conjugated polymeric visualization system
EnVision, linked with horseradish peroxidase using 3,3ʹ-
diaminobenzidine as the chromogen. All IHC reagents were
produced by DAKO, Glostrup, Denmark. Positive and nega-
tive quality controls were invariably performed and reacted
appropriately.
Quantification of Immunohistochemistry
Given the previously described cancer heterogeneity, which
encompasses the immunohistochemical reactivity,21 the
expression of each IHC marker was assessed both for inten-
sity and extent. The expression intensity was evaluated on
a scale ranging from 0 to 3 as follows: 0 = no expression, 1 =
weak, 2 = moderate and 3 = strong expression. The relative
extent (%) was measured as the fraction of cancer cells
expressing the given marker with the given intensity. The
final IHC score was calculated as the sum of the mathema-
tical products of the intensity and the relative extent.
The expression of MMR proteins was evaluated both
as binary variables (complete loss versus presence) and by
semiquantitative scoring as described above. The MMR
protein expression was reclassified then as low versus high
using the median value as the cutoff threshold: 1.39 for
MSH2; 1.9 for MSH6; 1.8 for PMS2; and 1.43 for MLH1.
Statistics
The statistical analysis was performed using the IBM SPSS
Statistics version 22.0 statistical software package
(International Business Machines Corp., Armonk,
New York, USA). The assumption check of normality was
performed by using the Shapiro-Wilk test. For descriptive
statistics, mean ± standard deviation (SD), median ± inter-
quartile range (IQR) and frequency were calculated as
appropriate. In short, mean values were presented for nor-
mally distributed continuous variables while medians were
presented for other continuous variables. Categorical data
were characterized by frequency. For mean values and fre-
quencies, 95% confidence intervals (CIs) were detected.
Nonparametric methods, including the Mann–Whitney test,
Spearman’s rank correlation and Pearson’s Chi-square, were
used for analytical statistics. Kruskal-Wallis’s one-way ana-
lysis of variance by ranks, followed by post hoc analysis
with Bonferroni correction, was applied to determine differ-
ences between three or more groups. A two-tailed p < 0.05
was considered statistically significant.
Results
The General Characteristics of the Study
Group
According to the inclusion and exclusion criteria, 553
consecutive cases of surgically treated primary colorectal
carcinoma were enrolled in the study (Table 2). Most of
the patients were elderly: 93.0% [95% CI: 90.5–94.8] of
them were older than 50. The median age was 71 (IQR,
15). The tumours were predominantly located in the left
part of the large bowel, as was seen in 395 cases or 71.4%
[67.5–75.0]. In regard to the morphology, adenocarcinoma
was found in 88.8% [85.9–91.2], mucinous adenocarci-
noma in 9.6% [7.4–12.3] and primary colorectal signet
ring cell carcinoma in 1.2% [0.6–2.6] of cases. There
were single cases (0.2% [0.0–1.0]) of medullary and undif-
ferentiated carcinoma as well. When evaluating the
T parameter, locally advanced tumors predominated: pT3
carcinoma represented 49.6% [45.4–53.7] and pT4 35.6%
[31.7–39.7], in contrast to pT2, which was seen only in
11.9% [9.5–14.9] of all cases. In terms of grade, moder-
ately differentiated (G2) cancers constituted 64.0%
[59.9–67.9] of the study group, and high-grade (G3) car-
cinoma was found in 25.7% [22.2–29.5] of the cases. As
for lymph node involvement, metastases in lymph nodes
(pN+) were found in 40.5% [36.5–44.6] of the patients. In
56 cases (10.1% [7.9–12.9]), only tumour deposits (pN1c)
were found within pericolonic or perirectal adipose tissue.
Table 1 Characteristics of the Primary Antibodies for Immunohistochemistry
Antigen Antibody Clonality Dilution Incubation Time, min. Pattern
E-cadherin MMAH NCH-38 1:50 60 Membranous
CD44 MMAH DF1485 1:50 60 Membranous
MSH2 MMAH FE11 1:100 20 Nuclear
MSH6 MRAH EP49 1:100 20 Nuclear
MLH1 MMAH ES05 1:50 20 Nuclear
PMS2 MRAH EP51 1:40 30 Nuclear
Abbreviations: MMAH, monoclonal mouse antibody against human antigen; MRAH, monoclonal rabbit antibody against human antigen; min, minutes.
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The median number of retrieved lymph nodes was 11
(IQR, 8).
In the whole study group, tumor invasion into lympha-
tic vessels was found in 352 cases or 63.6% [59.6–67.5],
while invasion into veins was observed in 23.0%
[19.6–26.6], perineural growth in 50.1% [45.9–54.2] and
intraneural growth in 31.1% [27.4–35.1] of the tumors.
Invasion into arteries was less frequent (3.4% [2.2–5.3]).
Overall, tumor necrosis was present in 295 cases, with
most of the carcinomas comprising a moderate amount
of necrosis, which was present in 146 cancers representing
49.5% [43.8–55.2] of tumors exhibiting any degree of
necrosis.
Pattern of the Inflammatory Reaction
Low-grade inflammation according to the redistributed
Klintrup-Mäkinen score was observed in 292 cases or
52.8% [48.6–56.9] and high-grade inflammation in 261
cases or 47.2% [43.1–51.4]. These groups showed statis-
tically significant age differences (p = 0.02). The mean age
of patients presenting with low-grade inflammation was
68.1 ± 10.6 years [66.9–69.3], contrasting with 69.6 ± 11.0
years [68.2–70.9] in those characterized by high-grade
peritumorous inflammation.
There were statistically significant differences (Table 3)
regarding pT distribution (p = 0.002) and the status of regio-
nal lymph nodes, reflected by pN (p < 0.001) in relation to
low- and high-grade inflammation. In assessing the morpho-
logical manifestations of the invasive growth, tumors sur-
rounded by low-grade peritumorous inflammation
significantly more frequently featured invasion into lympha-
tic vessels (p = 0.003), as well as intraarterial (p = 0.012),
intravenous (p = 0.017), perineural (p = 0.001) and intra-
neural (p = 0.01) growth (Table 3). The degree of inflamma-
tion was not statistically significantly different between right-
and left-sided colorectal carcinomas (p = 0.18), by the pre-
sence (p = 0.63) or extent (p = 0.11) of tumour necrosis or by
cancer grade (p = 0.07).
CLR (Figure 1) was found in 193 (34.9% [31.0–39.0])
cases. Most (85.5% [79.8–89.7]) of these tumours showed
a low density of lymphoid follicles. There were no statis-
tically significant differences in the distribution of CLR
density by cancer location (right versus left side of the
large bowel), pT, pN, grade, tumour invasion into sur-
rounding structures (blood or lymphatic vessels, nerves)
or necrosis (all p > 0.05). In contrast, statistically signifi-
cant differences were found by assessing the presence
versus the absence of CLR in regard to the manifestations
of invasive growth (Table 4).
Inflammatory cell subpopulation analysis (Table 5)
highlighted several significant associations between the
density of certain tumor-infiltrating cells and the invasive
capacity of the carcinoma, reflected by the manifestations of







Female 295 53.4 49.2–57.5
Male 258 46.6 42.5–50.8
Tumour localisation
Left sidea 395 71.4 67.5–75.0
Right sidea 158 28.6 25.0–32.5
WHO histological type
Adenocarcinoma 491 88.8 85.9–91.2
Mucinous carcinoma 53 9.6 7.4–12.3
Signet ring cell carcinoma 7 1.2 0.6–2.6





pT1 16 2.9 1.8–4.6
pT2 66 11.9 9.5–14.9
pT3 274 49.6 45.4–53.7
pT4 197 35.6 31.7–39.7
pN
pN0 273 49.4 45.2–53.5
pN1 156 28.2 24.6–32.1
pN1c 56 10.1 7.9–12.9
pN2 68 12.3 9.8–15.3
Grade
G1 56 10.1 7.9–12.9
G2 354 64.0 59.9–67.9
G3 142 25.7 22.2–29.5
G4 1 0.2 0.0–1.0
Invasive growth
Perineural invasion 277 50.1 45.9–54.2
Intraneural invasion 172 31.1 27.4–35.1
Lymphatic invasion 352 63.6 59.6–67.5
Invasion into veins 127 23.0 19.6–26.6
Invasion into arteries 19 3.4 2.2–5.3
Necrosis
Present 295 53.3 49.2–57.5
Focal 104 35.2 30.0–40.8
Moderate 146 49.5 43.8–55.2
Extensive 45 15.3 11.6–19.8
Absent 258 46.7 42.5–50.8
Note: aOf the large bowel.
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invasive growth (present versus absent). Interestingly, all
the statistically significant associations involved lymphatic
and perineural invasion that was linked to the density of
neutrophilic leukocytes (p-values: p = 0.01 and p = 0.04,
correspondingly), lymphocytes (p = 0.03 and p = 0.003) and
eosinophilic leukocytes (p = 0.008 and p = 0.01). In con-
trast, the macrophage counts lacked any statistically signifi-
cant associations (all p > 0.05).
EMT and Cancer Stem Cells
To assess the hypothetical relation between epithelial
mesenchymal transition, tumor stemness and inflamma-
tion, immunohistochemistry was performed to detect
E-cadherin and CD44 antigens (Figures 2 and 3). The
overall CD44 score was 1.28 [1.16–1.41], reaching 1.24
[1.10–1.37] in adenocarcinomas and 2.00 [1.61–2.38] in
mucinous carcinomas (p = 0.008). The overall E-cadherin
Table 3 Association Between Intensity of Peritumorous Inflammation by Klintrup-Makinen Grade and Morphological Features of
Colorectal Carcinoma
Parameter Low-Grade Inflammation High-Grade Inflammation p
Count F,% [95% CI] Count F,% [95% CI]
Tumour localisation
Left side 77 26.4 [68.3–78.3] 81 31.0 [25.7–36.9] 0.18
Right side 215 73.6 [21.7–31.7] 180 69.0 [63.1–74.3]
pT
pT1 6 2.1 [0.9–4.4] 10 3.8 [2.1–6.9] 0.002
pT2 29 9.9 [7.0–13.9] 37 14.2 [10.5–18.9]
pT3 132 45.2 [39.6–50.9] 142 54.4 [48.3–60.3]
pT4 125 42.8 [37.3–48.5] 72 27.6 [22.5–33.3]
pN
pN0 118 40.4 [34.9–46.1] 155 59.4 [53.3–65.2] < 0.001
pN+ 174 59.6 [53.9–65.1] 106 40.6 [34.8–46.7]
Grade of the carcinoma (G)
G1 26 8.9 [6.1–12.8] 30 11.5 [8.2-15.9] 0.07
G2 178 61.0 [55.3–66.4] 176 67.4 [61.5-72.8]
G3 87 29.8 [24.8–35.3] 55 21.1[16.6-26.4]
G4 1 0.3 [0.0–2.1] 0 0.0 [0.0–1.6]
Invasion
Perineural 167 57.2 [51.5–62.7] 110 42.1 [36.3–48.2] 0.001
Intraneural 103 35.3 [30.0–40.9] 69 26.4 [21.5–32.1] 0.01
Lymphatic 204 69.9 [64.4–74.8] 148 56.7 [50.6–62.6] 0.003
Into veins 77 26.4 [21.6–31.7] 50 19.2 [14.8–24.4] 0.017
Into arteries 15 5.1 [3.1–8.3] 4 1.5 [0.6–3.9] 0.012
Necrosis
Present 153 52.4 [46.7–58.1] 142 54.4 [48.3–60.3] 0.63
Absent 139 47.6 [41.9–53.3] 119 45.6 [39.7–51.7]
Focal 58 37.9 [30.6–45.8] 46 32.4 [25.2–40.5] 0.11
Moderate 78 51.0 [43.1–58.8] 68 47.9[39.8-56.0]
Extensive 17 11.1 [7.0–17.1] 28 19.7 [14.0–27.0]
Note: Statistically significant values are bolded.
Abbreviations: F, frequency; CI, confidence interval.
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score was 1.86 [1.78–1.94]: 1.91 [1.83–1.98] in adenocar-
cinoma and 1.48 [1.23–1.73] in mucinous carcinoma (p =
0.001). The CD44 expression was statistically significantly
(p = 0.026) higher in pN0 carcinomas than in metastatic
(pN+) tumors (Table 6). In contrast, CD44 levels did not
differ by pT, grade or manifestations of invasive growth.
The expression of E-cadherin showed statistically signifi-
cant differences by grade, but not by pT, pN or manifesta-
tions of invasive growth. As regards inflammation, the
presence of certain inflammatory cells or CLR, the only
significant finding was the association between a high
density of eosinophils and upregulation of E-cadherin.
MMR Protein Analysis
To see whether inflammation has any association with mis-
match repair status, IHC analysis of MMR proteins, namely
MSH2,MSH6,MLH1 andPMS2,was performed.A complete
loss of MSH2, MSH6, PMS2 and MLH1 was found in 0.8%
[0.0–4.9], 4.8% [2.0–10.4], 8.9% [4.9–15.3] and 3.2%
[1.0–8.3] of cases, respectively (Figure 4). Stratifying the
cases into high versus low level of MMR proteins, the
Mann–Whitney test showed a statistically significant differ-
ence in E-cadherin level by MSH2 and PMS2. CD44 only
showed a significant difference by PMS2 expression (Table 7).
There was no significant association between the grade of
peritumorous inflammation according to the Klintrup-
Mäkinen score and the expression of MMR proteins (Table
8), although individual cell analysis showed that an increased
density of tumor-infiltrating lymphocytes is associated with
MSH6 expression, ranging from1.66 [1.46–1.86] in caseswith
mild lymphocytic infiltration to 1.93 [1.74–2.11] in carcinomas
showing a moderate to high amount of lymphocytes.
Figure 1 Peritumorous inflammation in a colorectal carcinoma. (A): Crohn’s like lymphoid reaction (CLR), hematoxylin-eosin (HE) staining, original magnification (OM) 40×;
(B): inflammation in invasion site, HE, OM 100×; (C): mixed cellular composition in peritumorous tissue, HE, OM 400x.
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Discussion
Colorectal carcinoma is among the most frequent malig-
nant tumors worldwide, ranking third by incidence and
fourth by mortality.6 It accounts for 9.7% of the global
cancer burden.7 The geographic variations are significant:
the incidence rates differ tenfold, with the highest
occurring in Europe, North America and, in particular,
Australia and New Zealand, the later two having age-
standardized incidences of 44.8 and 32.2/100,000 males
and females, respectively.6
There are beneficial epidemiological trends, such as
declining mortality and increasing five-year survival rates
in many countries. For instance, in the USA, the five-year
survival rate (across all stages) has improved from 50.6% to
65.4% for colon cancer and from 48.1% to 67.7% in the case
of rectal cancer since the mid-70s. The mortality rates have
decreased in the USA, Australia and New Zealand, and the
majority of western Europe, as well as in some other
countries.6 Nevertheless, colorectal cancer still carries sig-
nificant mortality, accounting for 8.5% of oncological death
cases.7 The overall five-year survival rate is 64.9%, ranging
from 90% in early cases to 70.4% if the tumour has spread to
regional lymph nodes, and only 12.5% if distant metastases
are present.6 Therefore both additional prognostic markers
and treatment strategies are needed. Inflammation has been
targeted for both these directions.
The prognostic role of local and systemic inflammation
represents a hot topic in colorectal carcinoma research.
Table 4 Association Between Presence of CLR and
Manifestations of Invasive Growth of Colorectal Carcinoma
Type of Invasion Number of Cases;
Frequency, % [95% CI]
p
CLR Present CLR Absent




















Abbreviations: CLR, Crohn’s like lymphoid reaction; CI, confidence interval.
Table 5 Association Between Peritumorous Inflammatory Cell Density by Klintrup-Makinen Grade and Morphological Features of
Colorectal Carcinoma
Type of Identified Invasion Density of Inflammatory Cells: Number of Cases; Proportion, % [95% CI]
Absent Mild Moderate High p
Neutrophilic leukocytes
Perineural 202; 72.9 [67.4–77.8] 52; 18.8 [14.6–23.8] 17; 6.1 [3.8–9.7] 6; 2.2 [0.9–4.8] 0.04
Intraneural 126; 73.3 [66.2–79.3] 32; 18.6 [13.5–25.1] 12; 7.0 [3.9–11.9] 2; 1.2 [0.1–4.4] 0.13
Lymphatic 265; 75.3 [70.5–79.5] 57; 16.2 [12.7–20.4] 23; 6.5 [4.4–9.7] 7; 2.0 [0.9–4.1] 0.01
Intravenous 103; 81.1 [73.4–87.0] 16; 12.6 [7.8–19.6] 4; 3.2 [1.0–8.1] 4; 3.2 [1.0–8.1] 0.27
Intraarterial 16; 84.2 [61.6–95.3] 2; 10.5 [1.7–32.6] 0; 0.0 [0.0–19.8] 1; 5.3 [0.0–26.5] 0.48
Lymphocytes
Perineural 32; 11.6 [8.3–15.9] 147; 53.1 [47.2–58.9] 87; 31.4 [26.2–37.1] 11; 4.0 [2.2–7.1] 0.003
Intraneural 20; 11.6 [7.6–17.4] 92; 53.5 [46.0–60.8] 53; 30.8 [24.4–38.1] 7; 4.1 [1.8–8.3] 0.052
Lymphatic 39; 11.1 [8.2–14.8] 184; 52.3 [47.1–57.4] 115; 32.7 [28.0–37.7] 14; 4.0 [2.3–6.6] 0.03
Intravenous 14; 11.0 [6.6–17.8] 66; 52.0 [43.4–60.5] 43; 33.9 [26.2–42.5] 4; 3.2 [1.0–8.1] 0.88
Intraarterial 3; 15.8 [4.7–38.4] 13; 68.4 [45.8–84.8] 3; 15.8 [4.7–38.4] 0; 0.0 [0.0–19.8] 0.09
Eosinophilic leukocytes
Perineural 207; 74.7 [69.3–79.5] 64; 23.1 [18.5–28.4] 6; 2.2 [0.9–4.8] 0; 0.0 [0.0–1.7] 0.01
Intraneural 128; 74.4 [67.4–80.4] 39; 22.7 [17.0–29.5] 5; 2.9 [1.1–6.8] 0; 0.0 [0.0–2.6] 0.31
Lymphatic 264; 75.0 [70.2–79.3] 82; 23.3 [19.2–28.0] 6; 1.7 [0.7–3.8] 0; 0.0 [0.0–1.3] 0.008
Intravenous 92; 72.4 [64.1–79.5] 32; 25.2 [18.4–33.4] 3; 2.4 [0.5–7.0] 0; 0.0 [0.0–3.5] 0.21
Intraarterial 17; 89.5 [67.4–98.3] 2; 10.5 [1.7–32.6] 0; 0.0 [0.0–19.8] 0; 0.0 [0.0–19.8] 0.36
Note: Statistically significant values are bolded.
Abbreviation: CI, confidence interval.
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Table 6 CD44 and E-Cadherin Expression in Regard to Morphological Features of Colorectal Carcinoma
Parameter CD44 E-cadherin
Score 95% CI p Score 95% CI p
Tumour localisation
Left side 1.21 1.07–1.36 0.002 1.91 1.82–1.99 0.02
Right side 1.62 1.38–1.87 1.72 1.56–1.89
pT
pT1 2.22 0.63–3.81 0.23 1.91 0.00–5.48 0.07
pT2 1.28 0.89–1.67 2.04 1.77–2.31
pT3 1.27 1.08–1.46 1.90 1.81–1.99
pT4 1.39 1.19–1.59 1.72 1.59–1.85
pN
pN0 1.46 1.28–1.64 0.026 1.88 1.77–1.99 0.169
pN+ 1.18 0.96–1.39 1.80 1.69–1.92
Grade
G1 2.05 1.40–2.69 0.07 1.81 0.00–3.79 0.001
G2 1.24 1.09–1.38 1.95 1.88–2.04
G3 1.47 1.22–1.72 1.64 1.49–1.79
Invasion
Perineural
Present 1.22 1.02–1.42 0.28 1.78 1.67–1.90 0.30
Absent 1.38 1.23–1.55 1.90 1.80–1.99
Intraneural
Present 1.35 1.03–1.67 0.93 1.67 1.43–1.91 0.13
Absent 1.33 1.19–1.47 1.89 1.81–1.97
Lymphatic
Present 1.21 1.01–1.41 0.09 1.79 1.67–1.91 0.22
Absent 1.41 1.25–1.57 1.91 1.81–2.00
Into veins
Present 1.55 1.08–2.02 0.39 1.84 1.53–2.15 0.85
Absent 1.31 1.18–1.44 1.86 1.78–1.94
Inflammation
Low-grade 1.23 1.06–1.40 0.23 1.87 1.76–1.97 0.90
High-grade 1.42 1.23–1.61 1.85 1.74–1.96
Neutrophilic leukocytes
Low density 1.30 1.17–1.44 0.14 1.86 1.77–1.94 0.95
High density 1.55 1.23–1.88 1.88 0.66–3.11
Eosinophilic leukocytes
Low density 1.31 1.18–1.44 0.33 1.82 1.75–1.90 0.007
High density 1.58 1.05–2.10 2.31 1.88–2.10
Lymphocytes
Low density 1.26 1.09–1.42 0.33 1.85 1.75–1.96 0.85
High density 1.40 1.21–1.60 1.87 1.75–1.98
(Continued)
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Markers of systemic inflammation, e.g. Glasgow prognos-
tic score or neutrophil-to-lymphocyte ratio in peripheral
blood, have prognostic and predictive value in colorectal
cancer.37 Similarly, the prognostic value of inflammation
within the tumor microenvironment has been identified.38
Immunotherapy of colorectal cancer is developing in
several directions, including checkpoint blockade, adoptive
cell transfer and vaccination. Thus, anti-PD1 treatment has
been approved by the Food and Drug Administration for
microsatellite-unstable colorectal carcinomas. As most meta-
static colorectal cancer cases are microsatellite-stable and the
possibilities of immunotherapy are still limited in such
tumors, it has been advised to intensify the research of the
complex tumor microenvironment in association with micro-
satellite status.39
As the first target of our study, we aimed to assess the
inflammation in a large group of 553 consecutive, surgically
treated primary colorectal carcinomas. Colorectal cancer is
classically seen in aged people. In accordance with this,
most of our patients were diagnosed with the tumor after the
age of 50. The proportion of younger patients varies from
0.8% to 15% in different populations, even reaching 36% in
Iran.40,41 In the current study, it was 7.0%. Incidence rates
in younger adults have been increasing in the USA despite
the declining incidence and mortality in those aged 55 or
older. Thus, 20–29% of colorectal cancer cases in the USA
are diagnosed in patients younger than 55, and this worri-
some tendency is associated with either a lack of screening
in those younger than 50 or lower adherence to screening,
delayed diagnosis and more frequent presence of distant
metastases at the time of the first diagnosis.4 Although
colorectal cancer is known to be more frequent in males,6
our study shows a slight predominance of females, consti-
tuting 53.4% [ 49.2–57.5 %]. This can be explained by the
study design. In order to ensure complete evaluation of such
morphological traits as the deepest invasion, the status of
regional lymph nodes, morphological manifestations of
invasive growth and the characteristics of peritumorous
inflammation, we had to limit our study to surgically treated
cases. Thus, patients who were not suitable for surgery
because of advanced local tumour spread, the presence of
distant metastases or serious other (e.g. cardiovascular)
diseases were also not eligible for the study. Considering
the low compatibility with colorectal cancer screening in
our population (as discussed later), it is likely that males
might have a tendency to approach a doctor with a more
advanced tumor. A higher occurrence of cardiovascular
diseases in males is also a well-known phenomenon.42
Our cohort is characterized by a remarkable predomi-
nance of locally advanced tumors: pT3 carcinoma repre-
sented 49.6% [45.4–53.7] and pT4 35.6% [31.7–39.7], but
pT2 only 11.9% [9.5–14.9] of all cases. In parallel with this,
we observed a high rate of perineural and lymphatic invasion,
in contrast to previous studies in other countries.43 These data
likely reflect the overall increased proportion of advanced
cancer cases in the population, paralleling the reported low
compliance (only 9.6% in 2013) with the population-based
colorectal cancer screening in Latvia.44 In other European
countries, the participation rates in screening programs for
colorectal cancer range from 77 to 80% in Germany,45 68.2%
in the Netherlands, 19.9% in Croatia and 22.7% in the Czech
Republic. The acceptable minimum participation rate is 45%
but the desired target is more than 65%, thus screening in our
population cannot be considered efficient.3
The intensity of peritumorous inflammation showed
a statistically significant association with both the depth of
local invasion and the status of regional lymph nodes. Low-
grade inflammation was frequently observed in pT4 cases,
Table 6 (Continued).
Parameter CD44 E-cadherin
Score 95% CI p Score 95% CI p
Macrophages
Low density 1.31 1.14–1.47 0.64 1.87 1.78–1.96 0.97
High density 1.38 1.19–1.57 1.84 1.70–1.98
Crohn’s like lymphoid reaction (CLR) by density of lymphoid follicles per mm
Low density 1.46 1.25–1.67 0.93 1.84 1.75–1.94 0.38
High density 1.42 0.55–2.29 1.77 1.38–2.15
Note: Statistically significant values are bolded.
Abbreviation: CI, confidence interval.
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but it was significantly less common in pT3 carcinomas:
63.5% [56.5–69.9] versus 48.2% [42.3–54.1]. Previously,
an association between high-grade inflammation and T1-2
(as opposed to T3-4) had been reported.34 Thus, the Klintrup-
Mäkinen grade is shown to have distinct associations with
the full scope of pT, from the earliest pT parameters to the
advanced cases predominating in our study. Similarly, only
40.4% [34.9–46.1] of patients featuring low-grade inflamma-
tion were free of tumor metastases in the lymph nodes (pN0),
in contrast to 59.4% [53.3–65.2] in those presenting with
high-grade peritumorous inflammation. Our findings are in
accordance with Richards et al (2012), who also reported
a significant difference (p = 0.0039) between the grade of
inflammation in pN0 and pN+.34
As pT and pN are the strongest prognostic factors, our
results showing a statistically significant association
between high-intensity inflammation and a less extensive
cancer spread indirectly confirm the previously described
association between high-grade inflammation according to
the Klintrup-Mäkinen score and beneficial cancer-specific
or overall survival. However, the tendency toward a lower
intensity of inflammation in advanced cases also indicates
that peritumorous inflammation is not a simple secondary
phenomenon related to the extent of tissue damage and/or
compromised intestinal motility. Although necrosis is
a classic inciting factor of inflammatory reaction, there
was no association between cancer necrosis and high-
grade peritumorous inflammation. In addition, cases
Figure 2 E-cadherin expression in CRC. (A): moderate E-cadherin expression, OM 200×; (B): strong expression, OM 200×; (C): weak expression, OM 200×.
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presenting with intense inflammation significantly less fre-
quently featured specific manifestations of the higher inva-
sive capacity of the tumour, including perineural and
intraneural growth and invasion into lymphatic vessels,
veins and arteries. Thus, high-grade peritumorous inflam-
mation is associated with beneficial morphologic features
of colorectal carcinoma and is not secondary to tissue
damage and necrosis.
The development of lymphoid aggregates along the
invasive front of colorectal cancer was first described by
Graham and Appelman as early as in 1990.46 Since the
initial report, significant progress has been made regarding
both the pathogenetic understanding and the evaluation
methods. The considered phenomenon was initially
described as a Crohn’s disease-like reaction. Later,
Väyrynen et al proceeded with a detailed immunohisto-
chemical evaluation of the cellular composition of these
lymphoid aggregates. As there was no evidence of granu-
lomas, which represent the hallmark of Crohn’s disease,
the researchers suggested the term “colorectal cancer-
associated lymphoid reaction”.36 Initially, qualitative cri-
teria were used for analysis: the CLR was scored as 0
(absent Crohn’s disease-like reaction: no or a single lym-
phoid aggregate along the whole invasive front in all
Figure 4 MMR protein expression in CRC. (A,B): MSH2: no nuclear expression (A); strong nuclear expression (B); (C,D): MSH6: no nuclear expression (C); strong
nuclear expression (D); (E,F): MLH1: no nuclear expression (E); strong nuclear expression (F); (G,H): PMS2: no nuclear expression (G); strong nuclear expression (H).
Figure 3 CD44 expression in CRC. (A): intense CD44 expression, OM 100×; (B): no CD44 expression in tumor parenchyma, compared with surrounding stromal tissue,
OM 200×.
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tumor slides) versus 1 (occasional lymphoid aggregates
with rare or absent germinal centres) versus 2 (numerous
lymphoid aggregates with germinal centres) as described
by Graham and Appelman (1990). Later, Väyrynen et al
reported on a quantitative assessment, which showed
excellent intra- and inter-observer agreement. Although
both approaches were useful for showing the association
between a high CLR count and longer survival,36,46 in our
study, we followed the recommendations for computer-
assisted quantitative evaluation36 given the high accuracy
and low observer-related variability.
The association between CLR count and TNM parameters
is still controversial. Initially, Graham andAppelman observed
that CLR was associated with transmural invasion (in contrast
to cancer limited to the intestinal wall) but lower incidence of
metastases in regional lymph nodes. In addition, there was an
association with right-sided location in the context with trans-
mural growth,46 suggesting an impact of MMR-deficient
tumors. Using a quantitative approach analogously to the
current study, Väyrynen et al identified a significant associa-
tion between CLR count and pT in a retrospective cohort of
418 patients,36 but a trend was only observed in a prospective
cohort comprising 117 patients.36 We did not find significant
associations with pT and pN. The lack of association with
grade and pN is in accordance with previous studies.36 This
conclusion indirectly indicates that CLR density can be an
independent variable to be included in morphological proto-
cols and algorithms of computed-based whole-slide analysis.
Interestingly, the mere presence or absence of CLR46 did
show statistically significant associations with the morpho-
logical manifestations of invasive growth. Cancers not sur-
rounded by any CLR significantly more frequently displayed
lymphatic (p < 0.001), perineural (p < 0.001), intraneural (p <
0.01) and intravenous (p < 0.005) invasion. Thus, the prog-
nostically important threshold identified by Väyrynen et al
through ROC analysis of survival may be more related to the
outcome of the disease than to a particular morphological
profile of the tumor, thereby again suggesting indirectly an
independent protective role of immune and inflammatory
reaction that is not simply proportional to tumor burden.
Immunoscore,47,48 using the densities of CD3-positive
and CD8-positive lymphocytes, has been advised for evalu-
ating the status of the local immune system in colorectal
cancer. However, the availability of computer-based immu-
nohistochemical assessment has been questioned.34,35 There
is a strong trend of achieving most tumor microenvironment
characteristics in routine slides stained by hematoxylin-
eosin.34,38 In the near future, the same slides might serve as
the basis for computer-based assessment complementing
whole-slide scanning.49 Therefore we decided to evaluate
the cellular composition of the inflammatory infiltrate on
the hematoxylin-eosin basis. In addition, IHC, e.g. for
CD68, can be less specific than expected34 due to back-
ground or cross-reactivity issues. The possibility of counting
cells reliably in HE slides was shown by Richards et al, who
reported reasonable inter-observer variabilities, reaching
0.92 for lymphocytes, 0.80 for plasmatic cells and 0.92 for
eosinophils.34 In addition to the classically tested relations
with pTNM,35 we also evaluated the association with the
manifestations of invasive growth.
The density of eosinophils (p = 0.008), neutrophils (p =
0.01) and lymphocytes (p = 0.03) showed statistically
significant associations with cancer invasion into
Table 8 Mismatch Repair Protein Expression in Regard to








Mean IHC Score [95% CI]
MSH2 1.36 [1.18–1.55] 1.49 [1.32–1.66] 0.42
MSH6 1.66 [1.45–1.87] 1.92 [1.74–2.10] 0.09
PMS2 1.52 [1.31–1.73] 1.40 [1.18–1.62] 0.51
MLH1 1.41 [1.21–1.60] 1.23 [1.03–1.43] 0.26
Abbreviations: IHC, immunohistochemistry; CI, confidence interval.
Table 7 E-Cadherin and CD44 Levels in Regard to Mismatch Repair Protein Expression in Colorectal Carcinoma
MMR Proteins E-Cadherin: Mean IHC Score [95% CI] CD44: Mean IHC Score [95% CI]
Low MMR High MMR p value Low MMR High MMR p
MSH2 1.72 [1.61–1.82] 1.91 [1.81–2.01] 0.008 1.39 [1.17–1.60] 1.29 [1.15–1.43] 0.35
MSH6 1.79 [1.69–1.90] 1.81 [1.70–1.93] 0.54 1.22 [1.04–1.41] 1.38 [1.21–1.57] 0.27
PMS2 1.71 [1.60–1.82] 1.95 [1.85–2.05] 0.013 1.43 [1.24–1.62] 1.17 [1.00–1.34] 0.05
MLH1 1.83 [1.72–1.95] 1.87 [1.77–1.96] 0.97 1.33 [1.13–1.53] 1.33 [1.16–1.50] 0.80
Note: Statistically significant values are bolded.
Abbreviations: MMR, mismatch repair; IHC, immunohistochemistry; CI, confidence interval.
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lymphatic vessels. Perineural growth was associated with
the same cellular players: lymphocytes (p = 0.003), eosi-
nophils (p = 0.01) and neutrophils (p = 0.04). Thus, the
densities of particular inflammatory cells, evaluated in
regard to the pattern of tumor growth, cluster in
a distinct morphological syndrome of lymphatic and peri-
neural invasion. These morphological manifestations of
infiltrative growth are remarkable as the most sensitive
markers of invasion due to the thin tissue layer subjected
to damage. However, they are also the most frequent
among the morphological signs of cancer invasion, thereby
increasing the power of statistical analysis. Our study
might be more capable of detecting the associations
between the density of neutrophils, eosinophils and lym-
phocytes and the pattern of tumor invasion because the
present cohort is characterized by a predominance of
advanced tumors and hence a high frequency of manifes-
tations of invasive growth. Although further research is
clearly necessary to test both the reported findings and the
intra- and inter-observer variability, we strongly suggest
that evaluation of the inflammatory infiltrate should be
included in the routine diagnostic evaluation of colorectal
cancer tissues, in order to gain experience and obtain data
for further computer-based analysis.
Previously, high numbers of stromal eosinophils in
colorectal cancer have been reported to show an associa-
tion with a lower tumor stage and better overall and
cancer-specific five-year survival, as reflected by hazard
ratios for death of 0.61 (95% CI: 0.36–1.02; p = 0.02) and
0.48 (95% CI: 0.24–0.93; p = 0.01), respectively.50
Further, a higher density of peritumoral eosinophils was
significantly associated with lower T, N and G, the absence
of vascular invasion, and longer progression-free and can-
cer-specific survival.51
The previous findings on neutrophilic leukocytes infil-
trating colorectal carcinoma are more controversial.52 High
counts of intratumoral neutrophils correlated with a higher
pT, pM and stage. This was also an independent adverse
prognostic factor.53 Neutrophil infiltration in cancer cells
has been demonstrated as being an independent predictor
of lymph node metastasis.54 In contrast, a Swedish research
team from Umeå University found that neutrophil infiltra-
tion in the tumor front was a favorable prognostic factor in
early colorectal carcinoma.55 These controversies might be
explained by the duality of neutrophils comprising both
a tumor-suppressive N1 subpopulation and tumor-
supportive N2 neutrophils.52 The N1 versus N2 phenotype
of tumor-infiltrating neutrophils depends on the signals
encountered in the cancer microenvironment,52 which
might be stage-dependent.
The CD44 protein is a transmembrane adhesion mole-
cule. It is involved in the cell-cell or cell-matrix interaction,
as well as in cell migration. CD44 is one of the markers for
identifying cancer stem cells, characterized by self-renewing,
clonogenicity, metastatic spread and resistance to
chemotherapy.56 Multiple morphological studies and
reviews57 have been devoted to the CD44 expression in
colorectal cancer, although they have led to controversial
findings. When analyzing 174 patients, more frequent
expression was found in G1 and G2 carcinomas (75.8%
versus 44.4% in G3; p = 0.037), pN0 (85.7% versus 66.3%
in pN+; p = 0.004) and cases lacking lymphatic invasion
(88.6% versus 69.2%; p = 0.011). There was no association
with pT (p = 0.826).58 In contrast, the authors of a recent
meta-analysis concluded that CD44 overexpression in color-
ectal carcinoma is an unfavorable prognostic factor that pre-
dicts a high grade and metastases in lymph nodes and distant
sites.59 Hong et al reported on 162 immunohistochemically
investigated colorectal cancer cases. This team did not find
statistically significant associations between pT (p = 0.578),
pTNM stage (p = 0.711), G (p = 0.144) or age (p = 0.690).
Nevertheless, they observed a stronger expression in primary
carcinoma than in paired lymph node metastasis, character-
ized by p < 0.001. A loss of CD44 was an independent
prognostic factor for cancer-free (p = 0.028) but not overall
(p = 0.107) survival.28 In 60 patients, a positive expression of
CD44 was associated with histological type, but not pT,
pN, M, pTNM stage or G. No association with perineural
or lymphovascular invasion was found.60 In mRNA and
protein assessment, no differences in CD44 levels were
seen by age (p = 0.500), grade (p= 0.026), pT (p = 0.613),
lymphovascular (p = 0.422) or perineural (p = 0.734)
invasion.61 After preoperative chemoradiotherapy, high
levels of CD44 protein in rectal cancer were associated
with ypN0 (p = 0.009) but not with age (p = 0.734), ypT
(p = 0.666), grade and histological type (p = 0.515), or
lymphatic (p = 0.078) or vascular (p = 0.077) invasion.62 In
a National Cancer Institute study, there was no association
between CD44 and overall survival, grade and histological
type, cancer stage and lymph node status.63 In rectal cancer,
CD44 did not correlate with age, pT, lymph node metastasis,
or lymphatic and blood vessel invasion.64
In our study, we confirmed a significant association
between CD44 expression and pN (p = 0.026), as well as
with tumor histogenesis (p = 0.008). A statistically signif-
icantly higher expression was found in right-sided
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carcinomas (p = 0.002), paralleling and expanding the
observations of more frequent (p = 0.02) expression in
colonic adenocarcinomas than in rectal tumours.60 CD44
levels also showed a significant association with the
expression of PMS2 protein (p = 0.05).
Malignant tumor progression is closely associated with
inflammatory processes, and interaction between pro- and
anti-inflammatory cytokines and it has been previously
described by different authors. In CRC pathogenesis, as
well as in other malignancies, the role of chronic inflamma-
tion has been widely discussed. Within blood tests, elevated
levels of interleukin-6 (IL-6), interleukin-17 (IL-17), TNF
and other cytokines are associated with cancerogenesis.37
Tumor-associated macrophages (TAMs) are one of the
sources of cytokines, and their released IL-10 levels increase
in patients with CRC, especially in advanced stages.65 Yan
et al found a correlation between a high TAM count in gastric
cancer and its progression, related to EMT.66 IL-4, one of the
anti-inflammatory cytokines produced by T cells, inhibits the
expression of E-cadherin and carcinoembryonic antigen
(CEA), and its levels are increased in patients with CRC
compared to healthy patients.67 Interleukin-8 levels, as
described by Kantola et al, increase in patients with CRC,
especially in poorly differentiated carcinomas.68
Chen et al, found a relation between high NLR (neu-
trophil/lymphocyte ratio) and elevated cytokine levels,
while lower NLR was associated with lower levels of
cytokines.69
Within our study, we found that high-grade inflamma-
tion, consisting of high amounts of granulocytes and lym-
phocytes, is associated with more frequent involvement of
anatomical structures, such as lymph vessels and nerves.
However, further analysis of monocyte-related changes
and the NLR rates within blood should be done.
The authors of several studies exploring inflammatory
pathways have identified mechanisms of CD44 upregula-
tion by inflammatory cells and/or the relevant mediators.
TNF-beta, produced by activated lymphocytes, induces
NF-kappaB activation and EMT (including upregulation
of vimentin and downregulation of E-cadherin) and
enhances stemness by CD44 expression in colorectal
cancer.70 Macrophages that were polarized to M1 state
via infection by commensal microorganisms, such as
Enterococcus faecalis, activated the Wnt/beta-catenin
pathway and upregulated CD44 in murine colonic epithe-
lium. The effect was partially mediated via TNF-alpha.71
In turn, colon adenocarcinoma overexpressing CD44
recruits tumour-associated macrophages.72 Reciprocal
interactions between tumor-associated macrophages and
CD44-expressing malignant cells promote tumorigenicity
in colorectal cancer.73 Crosstalk between stromal fibro-
blasts and colorectal cancer cells also promotes EMT and
CD44 expression.74 The crosstalk between fibroblasts and
colorectal carcinoma is also evidenced under the condi-
tions of chemotherapy when it involves interleukin IL-17A
messaging to maintain CD44-positive cancer stem cells.75
Nonsteroidal anti-inflammatory drugs suppress CD44-
expressing stem cells of colorectal carcinoma via COX-2
inhibition. This effect was evident in cell culture as well as
in an in vivo mouse xenograft model.76 Despite these
multiple observations linking CD44 and inflammation in
colorectal carcinoma, we did not find any significant asso-
ciations in surgical material. CD44 levels were not related
to the grade of inflammation according to the Klintrup-
Mäkinen score, cellular components of peritumoral inflam-
mation or the presence of CLR. Thus, the upregulation/
loss of CD44 seems to be influenced by a complex net-
work of molecular events, and therefore morphological
evaluation of whole tissues represents an important sup-
plement to in vitro and experimental animal studies.
In colorectal cancer, there is a close association
between CD44 and EMT, characterized by a loss of epithe-
lial markers, such as E-cadherin, and the development of
mesenchymal traits in the tumor cells. EMT leads to
enrichment with CD44-positive cancer stem cells.77
Snail, a known activator of EMT, induces
CD44expressing cell differentiation.78 CD44 is
a canonical target of the Wnt cascade. In turn, CD44
regulates Wnt signalling through a positive feedback
loop.79 However, in a large immunohistochemical study
from Seoul comprising 174 patients, the loss of E-cadherin
was associated with the loss of CD44,58 thereby highlight-
ing once again the complexity of molecular networks in
cancer tissues as opposed to in vitro experiments.
E-cadherin is a calcium-dependent epithelial transmem-
brane glycoprotein supporting epithelial layer integrity and
polarity. The loss of E-cadherin, or displacement of it apart
from the cell membrane, weakens intercellular adhesion and
facilitates cell migration and invasion.56,58 However,
E-cadherin may have dual functions in colorectal cancer.
Downregulation of E-cadherin is known to develop within
epithelial mesenchymal transition associated with higher
invasive and metastatic potential of cancer cells and, con-
sequently, a worse outcome. Thus, an immunohistochemical
loss of E-cadherin was associated with shorter cancer-free
(p = 0.002) and overall survival (p = 0.007) in 286 cases of
Dovepress Briede et al
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colorectal cancer.80 In contrast, E-cadherin positivity in
colorectal cancer stem cells is associated with a higher
growth potential in vivo than seen in the E-cadherin nega-
tive subpopulation of cancer stem cells.81 Combined assess-
ment of E-cadherin and CD44 in colorectal cancer has been
shown to have a higher prognostic value than isolated
evaluation of single markers.29,82 The pathways of EMT
induction and stemness differ by MSI status. Twist1
induced EMT and CD44 via AKT/GSK-3beta/beta-catenin
and AKT/NF-kappaB pathways in MSS cells, while only
the beta-catenin pathway was activated in MSI colorectal
cancer cells.83 In contrast, Park et al reported that CD44
expression did not differ by MSI status.84
Several morphological studies have been devoted to
E-cadherin expression in colorectal cancer. When analyz-
ing 174 patients, the expression was statistically signifi-
cantly more frequent (p = 0.007) in G1 and G2 carcinomas
(78.2% versus 33.3% in G3). There was no association
between pT (p = 0.697), pN (p = 0.456) and lymphatic
invasion (p = 0.710) as reported by Seo et al (2015).58 In
our study, we also found significant associations between
E-cadherin score and cancer grade, but not spread, as
reflected by pT and pN. There was a statistically signifi-
cant link (p = 0.007) between the level of E-cadherin and
the density of eosinophils. Interestingly, a protective asso-
ciation (p = 0.003) has been reported between an increased
eosinophil blood count and a decreased risk of colorectal
cancer, with hazard ratios of 1.0, 0.70 [0.50–0.98] and
0.58 [ 0.40–0.83] across the tertiles of absolute eosinophil
count.85 A protective role has also been ascribed to stro-
mal eosinophils in colorectal carcinoma.50 Thus, upregula-
tion of E-cadherin is associated with beneficial tumor
features, possibly including the recruitment of eosinophils
as one of the mechanisms.
Previously, it has been shown that MLH1 and MSH2
immunohistochemistry has acceptable sensitivity and spe-
cificity for high MSI status: 92.3% and 100%,
respectively.86 Therefore this approach has been applied
in other studies.35 Here, we extended the IHC for MMR
proteins with MSH6 and PMS284 that might be implicated
in at least 10–15% of pedigrees affected by Lynch
syndrome,87 which is known to occur in Latvia as well.88
The levels of certain MMR proteins showed associations
with the molecular characteristics of colorectal cancer.
Thus, a higher mean score of E-cadherin was significantly
associated with the presence of MSH2 (p = 0.008) and
PMS2 (p = 0.014), while a lower expression of CD44 was
significantly associated with PMS2 (p = 0.05). The
expression of MMR proteins did not differ between cases
featuring a high versus a low intensity of inflammation
according to two-tiered Klintrup-Mäkinen grading.
The key strengths of the current study include the
representative in-depth analysis and the high relevance to
human pathology as the full complexity of pathogenetic
networks is displayed in the affected tissues. The evalua-
tion of inflammation and malignancy as well as of mor-
phology and immunophenotype was carried out using an
integrated approach.
To the best of our knowledge, based on a search of
PubMed, there are no preceding studies that directly assess
the correlations between inflammation, EMT, stem cell
differentiation and MMR protein expression in the tissues
of colorectal carcinoma. Despite the experimental evi-
dence that provides the theoretical background to link
these processes, we found no statistically significant asso-
ciations in surgical material that indirectly point to
a complex, balanced network of cellular and molecular
interactions. When elaborating and planning innovative
molecular-based or anti-inflammatory treatment options,
this complexity must be accounted for.
In order to ensure representative data, the enrolled
cohort was of an appropriate size, comprising 553 patients
subjected to surgical treatment for primary colorectal car-
cinoma. Further, as consecutive cases were studied, the
tissues represent the full, intricate landscape of events in
a cancer microenvironment. The analysis of inflammation,
morphological features and immunophenotype of carci-
noma was performed in whole-tissue sections that reflect
cancer heterogeneity more completely than biopsies or
tissue microarrays. The tissue-based assessment of color-
ectal carcinoma has an advantage over in vitro or animal
studies as our approach shows the result of the cellular and
molecular interplay in cancer-related inflammation. To
ensure accuracy, which is the mainstay of all scientific
studies, elaborate, protocol-based morphological evalua-
tion was accomplished by two experienced pathologists
in line with WHO and UICC recommendations.
In conclusion, here we present an extensive, detailed
study of inflammation in association with morphological
and immunohistochemical features of colorectal carci-
noma. We have shown that high-grade peritumorous
inflammation is associated with beneficial morphologic
features of colorectal carcinoma and is not secondary to
tissue damage and necrosis.
The densities of particular inflammatory cells, includ-
ing neutrophils, eosinophils and lymphocytes, in cancer
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tissues cluster in a distinct morphological syndrome of
lymphatic and perineural invasion, confirmed by statisti-
cally significant associations. These morphological mani-
festations of infiltrative growth are remarkable as the most
sensitive markers of invasion due to the thin tissue layer
subjected to damage. However, those are also the most
frequent among the morphological signs of cancer inva-
sion, thereby increasing the power of statistical analysis.
Our study might have a greater ability to detect these
associations because the present cohort is characterized
by a predominance of advanced tumours and hence
a high frequency of manifestations of invasive growth.
The complete absence of CLR is statistically signifi-
cantly associated with more frequent manifestations of
invasive growth, including lymphatic, perineural, intra-
neural and intravenous invasion. However, the CLR den-
sity is not related to cancer spread by pTN. These findings
indirectly indicate an independent protective role of
immune reaction that is not simply proportional to tumor
burden. Thus, we suggest that peritumorous inflammation
according to Klintrup-Mäkinen score and CLR density
should be included in morphological protocols and algo-
rithms of computed-based whole-slide analysis for routine
evaluation of surgical materials.
Further, inflammation according to Klintrup-Mäkinen
grade and CLR are not dependent on the expression of
E-cadherin, CD44 and MMR proteins. Our study high-
lights the complex associations between inflammation,
tumour morphology, EMT, stem cell differentiation and
MMR protein expression in surgical tissue material.
Conclusions
High-grade peritumorous inflammation according to
Klintrup-Mäkinen score is associated with beneficial mor-
phological features of colorectal carcinoma, including
a lower pT, and less frequent lymph node metastases and
manifestations of invasive growth. Although necrosis is
a classic inciting factor of inflammatory reaction, there
was no association between cancer necrosis and high-
grade inflammation. Thus, peritumorous inflammation is
not secondary to tissue damage (by tumor burden and/or
invasive growth) and necrosis.
The densities of particular inflammatory cells, including
neutrophils, eosinophils and lymphocytes, cluster in a distinct
morphological syndrome of lymphatic and perineural inva-
sion, confirmed by statistically significant associations. These
morphological manifestations of infiltrative growth are
remarkable as the most frequent and also most sensitive
markers of invasion due to the thin tissue layer subjected to
damage. Our study might have a greater ability to detect these
associations because the present cohort is characterized by
a predominance of advanced tumors and hence a high fre-
quency of manifestations of invasive growth.
The complete absence of CLR is statistically significantly
associated with more frequent manifestations of invasive
growth, including lymphatic, perineural, intraneural and intra-
venous invasion. However, Crohn’s disease-like lymphoid
reaction is not linked to cancer spread by pTN. These findings
indicate an independent protective role of inflammatory and
immune reaction that is not simply proportional to tumor load.
Therefore we suggest that evaluation of peritumorous inflam-
mation by Klintrup-Mäkinen score and CLR should be
included in morphological protocols and algorithms of com-
puter-based whole-slide analysis.
Further, inflammation according toKlintrup-Mäkinen grade
and CLR density in surgical tissue material is not associated
with the expression of E-cadherin, CD44 and MMR proteins.
Our study highlights the complex associations between inflam-
mation, tumor morphology, EMT, stem cell differentiation and
MMR protein expression in surgical tissue material.
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